Abstract

The APOTS-Ω v1.0 platform is a conceptual, non-invasive, closed-loop ocular transport system designed to enhance the posterior delivery of topically applied therapeutics to the macular region of the eye without intra-vitreal injection. The system combines low-energy phased ultrasound, adaptive vortex-mode acoustic transport, conductive hydrogel coupling interfaces, smart nanoparticle eye-drop carriers, thermal-stabilizing biointerfaces, and real-time safety monitoring into a unified transport-conditioning architecture.

Unlike conventional ultrasound drug-delivery concepts that rely primarily on brute-force permeability enhancement, APOTS-Ω is designed around controlled transport engineering using low-intensity adaptive fields, posterior-biased streaming geometries, delayed-release nanocarriers, and distributed safety feedback systems. The platform seeks to improve posterior ocular bioavailability while minimizing thermal, cavitation, retinal, and lens exposure risks.

The proposed system uses:

  • low-frequency ultrasound to transiently and reversibly increase posterior scleral permeability,

  • mid-frequency phased vortex fields to induce low-energy vitreous and orbital micro-streaming,

  • conductive hydrogel coupling layers to improve acoustic transmission and thermal stability,

  • and acoustically responsive nanocarrier eye-drops to improve posterior migration and controlled release behavior.

The system is intended solely as an open conceptual research architecture for professional laboratory evaluation. It is not a medical device, has not been clinically tested, and must undergo extensive phantom, ex vivo, animal, and regulatory safety testing before any human consideration.

If validated experimentally, APOTS-Ω could represent a pathway toward reducing dependence on repeated intra-vitreal injections for posterior ocular diseases by enabling safer and more effective non-invasive drug transport to the posterior eye.

OPEN RELEASE STATEMENT

This concept is released openly, freely, non-exclusively, and without patent restriction for any qualified research institution, biomedical laboratory, university, or medical engineering team to study, prototype, validate, modify, or extend.

Creative Commons License

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.

Download

Share

COinS